Rising Prevalence of Allergic Rhinitis & Allergic Asthma in NA & EU
The increasing burden of allergic respiratory conditions across North America and Europe represents a fundamental demand driver for immunotherapy interventions. According to the U.S. Centers for Disease Control and Prevention's National Health Interview Survey (NHIS) 2021 data, 25.7% of American adults (approximately 66 million individuals) reported diagnosed seasonal Allergies, which include hay fever, allergic rhinitis, and allergic conjunctivitis. Among children aged 0–17 years, 18.9% had seasonal Allergies, affecting roughly 14 million pediatric patients. The CDC further reports that approximately 65.9% of children with asthma have comorbid allergic conditions, creating substantial overlap populations requiring targeted immunotherapy approaches.
In Europe, the burden remains equally significant. A comprehensive 2018 National Health and Wellness Survey across five major European markets (France, Germany, Italy, Spain, and the United Kingdom) documented an asthma prevalence of 6.7% among adults, with the UK reporting the highest rates at 10.4%. Notably, 52.0% of diagnosed asthma patients rated their condition as mild, 27.9% as moderate, and 20.1% as severe indicating substantial unmet medical need among moderate-to-severe patients who represent the primary candidates for biologic immunotherapy. The CDC's longitudinal surveillance confirms asthma prevalence among American adults increased significantly from 2013 through 2021, with 8.0% of adults (20.3 million) reporting current asthma in 2021, while children maintained a 6.5% prevalence rate. These epidemiological trends, combined with documented healthcare utilization disparities and persistent uncontrolled symptoms in approximately 50% of pediatric and 62% of adult asthma patients, create sustained market demand for disease-modifying immunotherapy interventions that address underlying Type 2 inflammation rather than merely controlling symptoms.
Advancements in Biotechnology
The immunotherapy market has been fundamentally transformed by breakthrough biotechnology innovations, particularly in monoclonal antibody engineering and manufacturing capabilities. The industry has entered what researchers characterize as "Era 4" of therapeutic antibody development (2024+), characterized by production culture titers exceeding 8 g/L and maximum single-product manufacturing volumes surpassing 10 tons annually, a tenfold increase from capacity levels just five years prior. These manufacturing advances have direct implications for the accessibility and cost structures of immunotherapy, enabling broader patient populations to access previously supply-constrained biologics.
The FDA's approval data demonstrates unprecedented momentum in biologic immunotherapy development. From January 2023 through October 2024, the agency approved 16 first-in-class macromolecular drugs, with antibody drugs representing the dominant modality. Notably, 8 first-in-class antibody/ADC drugs received approval during this 22-month period—comparable to the entire 2019–2022 approval volume and substantially exceeding the 2011–2014 period. Specific immunotherapy breakthroughs include the FDA's December 2021 approval of Tezepelumab (Tezspire), the first biologic targeting thymic stromal lymphopoietin (TSLP) for severe asthma without phenotype or biomarker limitations, representing a paradigm shift toward precision immunotherapy.
Manufacturing technology advances have enabled production scalability that supports market expansion. The U.S. Department of Health and Human Services announced in 2023 a multi-year initiative to bolster domestic manufacturing capabilities for monoclonal antibodies, ensuring supply chain resilience. Johnson & Johnson's June 2024 expansion of biologics manufacturing capacity in Pennsylvania, representing an investment exceeding $500 million, exemplifies the industry's commitment to scaling immunotherapy production. These infrastructure investments, combined with process innovations such as single-use bioreactors and continuous manufacturing platforms, have reduced the cost-of-goods and enabled the commercial viability of next-generation immunotherapies targeting smaller patient populations.
Increasing Research and Development Investment
Pharmaceutical and biotechnology companies have substantially increased R&D commitments to immunotherapy programs, reflecting confidence in the therapeutic modality's commercial potential and clinical value proposition. Regeneron Pharmaceuticals, developer of the blockbuster immunotherapy dupilumab (Dupixent), invested $4.4 billion in R&D during 2023, representing 34% of total revenue. This investment intensity continued into 2024, with Q4 2024 R&D expenses reaching $1.412 billion, a 20% year-over-year increase driven by mid- and late-stage clinical pipeline advancement. The company's 2023 Responsibility Report explicitly identifies immunology and inflammation as core therapeutic focus areas, with ongoing programs targeting grass and birch pollen Allergies in Phase 3 development. At the industry level, the European Federation of Pharmaceutical Industries and Associations (EFPIA) documented that the research-based pharmaceutical industry invested approximately €50 billion in R&D across Europe in 2023. This investment occurs within a competitive landscape where North America captured 53.3% of world pharmaceutical sales, with 67.1% of new medicines launched during 2018–2023 first reaching the U.S. market, indicating North America's central role in immunotherapy commercialization.
AstraZeneca's 2023 Annual Report illustrates strategic prioritization of immunotherapy expansion, with the company completing more than 60 major business development transactions over three years, including the November 2023 exclusive license agreement for AZD5004 involving $185 million upfront and up to $1.81 billion in future milestones. The investment trajectory extends beyond established players to specialized biotechnology firms. Eli Lilly committed nearly $1.0 billion in March 2023 for a monoclonal antibody manufacturing facility in Ireland, targeting novel clinical treatment production by 2026. This capital deployment reflects expectations of sustained immunotherapy demand growth and the need for manufacturing capacity to support pipeline assets. The aggregate R&D investment patterns demonstrate industry consensus that immunotherapy represents a high-value therapeutic category warranting substantial resource allocation.
Increasing Pediatric Adoption
The expansion of immunotherapy indications into pediatric populations represents a significant market growth driver, supported by regulatory approvals and evolving treatment paradigms. The FDA's June 2022 approval of dupilumab for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis marked a watershed moment as the first systemic treatment (and only biologic) approved for this age group. This approval was based on the LIBERTY AD PRESCHOOL trial, which demonstrated that by week 52 of open-label extension treatment, 96.6% of pediatric patients achieved at least 50% improvement in Eczema Area and Severity Index scores, with 36.2% achieving clear or almost clear skin. The pediatric immunotherapy landscape has expanded rapidly across multiple indications. In October 2021, the FDA approved dupilumab for children aged 6 to 11 years with moderate-to-severe asthma characterized by an eosinophilic phenotype or oral corticosteroid dependence. Omalizumab's indication was expanded to include children aged 6–11 years in 2016, with utilization data showing a 58 per 100,000 children increase in Medicaid populations and 57 per 100,000 in commercial insurance following FDA approval, demonstrating immediate post-approval adoption.
